Keros Therapeutics (NASDAQ:KROS) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock.

A number of other equities research analysts have also commented on KROS. Scotiabank began coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective on the stock. Guggenheim started coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Finally, Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $89.11.

Keros Therapeutics Stock Performance

KROS stock opened at $59.56 on Thursday. Keros Therapeutics has a 52-week low of $27.02 and a 52-week high of $73.00. The company has a market capitalization of $2.15 billion, a P/E ratio of -11.57 and a beta of 1.23. The company has a fifty day moving average price of $54.33 and a 200-day moving average price of $51.94.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. As a group, sell-side analysts forecast that Keros Therapeutics will post -4.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Keros Therapeutics in the 2nd quarter worth approximately $1,118,000. Bank of New York Mellon Corp increased its holdings in shares of Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares during the last quarter. Swiss National Bank raised its position in shares of Keros Therapeutics by 22.0% during the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after buying an additional 9,000 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics during the 2nd quarter worth $532,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.